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2Abstract
Introduction. Cardiovascular involvement represents a well-known complication and the
primary cause of mortality, both in transfusion-dependent beta thalassemia major (β-TM) and in
transfusion-independent beta thalassemia intermedia (β-TI). In β-TM, heart iron overload is
considered the main cause of this complication. This is likely due to poor adherence to iron-
chelating therapy, resulting in the inability of the body to efficiently remove iron excess derived
from transfused red blood cell breakdown. Different clinical pictures may instead be evoked in
cardiovascular involvement occurring in β-TI; however, until now, no factor has emerged as the
major one responsible for these complications.
Design and Methods. In the present study, iron status, and lipid profiles in serum, as well as
lipid content in peripheral blood mononuclear cells (PBMCs) were evaluated in 70 adult β-TM
and in 22 adult β-TI patients. Ninety-two age-matched blood donors, free from any form of
thalassemia, were utilized as controls. The mRNA levels of genes involved in the regulation of
iron metabolism, such as interleukine 1 alfa (IL1α), tumor necrosis factor alfa (TNFα), as well
as those involved in cholesterol homeostasis, such as acetyl-coenzymeA: cholesterol
acyltransferase (ACAT-1), neutral cholesterol ester hydrolase (nCEH), and ATP binding
cassette-A (ABCA1), were also evaluated in PBMCs from the above subjects.
Results. In  β-TI  patients,  serum  iron,  transferrin  saturation  and  erythropoietin  levels  were
higher, while transferrin and hepcidin were lower, compared to both β-TM and controls.
Hepcidin and ILα mRNA levels were found to be reduced in β-TI-PBMCs, while those of TNFα
were increased. A reduction in total and high density lipoprotein cholesterol (TC and HDL-C) in
serum, and an accumulation of neutral lipids (NL), coupled with increased mRNA levels of
ACAT-1 and decreased nCEH in PBMCs were also observed in β-TI.
Conclusions. Since most of the parameters found to be altered in β-TI patients have a key role
in the initiation and progression of atherosclerosis, we suggest that cardiovascular complications
in these patients may be, at least partially, dependent on the occurrence of premature
atherosclerotic lesions.
Key words: thalassemia, iron, cholesterol, atherosclerosis.
Introduction
Beta (β) thalassemia is an inherited hemoglobin disorder characterized by reduced synthesis of β-
globin chains. The severity of the clinical course differentiates this heterogeneous disease into three
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3main subtypes: i) thalassemia major (β-TM ) ii) thalassemia intermedia (β-TI ) and iii) thalassemia
minor (β-TMI).1 β -TMI is never actively treated, however, although not life threatening on its own,
it can affect quality of life due to the effects of a mild to moderate chronic anemia. Patients with β-
TM have severe anemia which starts during the first months of life and requires life-long transfusion
therapy.1 Patients with β-TI have a later clinical onset with a milder anemia and, at least for the first
decades of their lives, they are usually transfusion-independent.2 If untreated, both forms of
thalassemia are complicated by the multiple effects of chronic hemolytic anemia, such as tissue
hypoxia, and by their compensatory reactions, including increased erythropoiesis with bone marrow
expansion and increased intestinal iron absorption.3
Nowadays, in β-TM patients, due to the early application of regular transfusion-chelation therapy,
compensatory reactions induced by hypoxia are strongly reduced. By contrast, in β-TI patients, who
did not undergo regular transfusions, tissue-hypoxia persists, and consequently they have bone
marrow expansion and increased rates (three to four times the normal ones) of intestinal iron
uptake.4 Cardiovascular complications are a main feature of the clinical spectrum of β-thalassemias.
They are the leading cause of death (up to 67%)5 and have been well documented only in β-TM.
The prominent finding in this condition is left ventricle (LV) dysfunction, which is attributed mainly
to myocardial overload of iron derived from transfused red blood cell breakdown that gradually
leads to cardiac failure and cardiogenic death.4 Although  β-TM  and  β-TI  share common basic
pathophysiological mechanisms, cardiovascular involvement may be different in the latter, also
considering the fact that no evidence of cardiac iron overload has been found in never-transfused or
minimally transfused β-TI patients.6 Recent studies indicated that endothelial dysfunction, the
precipitating factor in the atherosclerotic process, is an important cardiovascular risk determiner in
β-TI patients.7 Therefore, studies aimed at extending the knowledge of the mechanisms connecting
atherosclerosis to this type of thalassemia, might help to prevent and/or treat cardiovascular
complications in thalassemic subjects.
Among the numerous factors known to confer increased susceptibility to atherosclerosis, iron and
cholesterol merit particular consideration in β-TI patients.
It has been demonstrated that the presence of non-transferrin-bound-iron (free iron) in serum
generates free radicals which, in turn, cause oxidative vessel injury.8 Free oxygen radicals act
directly on the endothelial cells and have a close interaction with lipid peroxidation, causing a
modification of low-density lipoprotein (LDL) and facilitating LDL deposition, with the consequent
formation of atherosclerotic plaques.8
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4Accumulating evidence connects hepcidin expression to iron absorption regulation to iron
utilization by the erythroid precursors in bone marrow. Hepcidin inhibits duodenal iron absorption
as well as iron release from macrophages.9 Very low mRNA levels of this hormone have been
found in hepatic biopsies from β-TI10. It has also been reported that interleukin-1 alpha (IL-1α)
stimulates hepcidin transcription, indicating this cytokine as a possible iron metabolism regulator.  11
Hypercholesterolemia is considered one of the most important risk factors in the development of
atherosclerosis; however, concentrations of total cholesterol (TC), and LDL-C and/or high-density
lipoprotein cholesterol (HDL-C) have been found to be reduced in thalassemic patients12, those in
β-TI being even lower than those in β-TM.13 These findings make it unlikely that cholesterolemia is
responsible for atherogenic risk in these patients.
However, it is important to consider that, besides cholesterolemia, atherosclerosis is associated with
profound changes in intracellular lipid metabolism (i.e. monocyte-macrophages cholesterol ester –
CE – accumulation).14Therefore, before excluding cholesterol as a risk factor for endothelial
dysfunction in β-TI patients; cholesterol homeostasis at a cellular level must be investigated.
Starting from these considerations, we measured lipid and iron metabolism in serum and in
peripheral blood mononuclear cells (PBMCs) from β-TI and β-TM patients and controls. In addition
the mRNA levels of genes controlling iron homeostasis, such as hepcidin, IL-1a and tumor necrosis
factor alpha (TNFα), as well as cholesterol homeostasis, such as acetyl-coenzymeA: cholesterol
acyltransferase (ACAT-1), the enzyme responsible for cholesterol intracellular esterification,
neutral cholesterol ester hydrolase (nCEH), responsible for hydrolysis of CE from cellular storage
and ATP binding cassette-A (ABCA1), a mediator of cellular cholesterol efflux, were also
determined in PBMCs from enrolled subjects.
Material and Methods
Subjects and blood sampling
Seventy β-TM and twenty-two β-TI adult patients under treatment at the Day Hospital of Ospedale
Regionale per le Microcitemie, Centro Talassemici Adulti (Cagliari, Italy) were enrolled. Ninety-
two age-matched blood donors, free from any form of thalassemia, enrolled at the Transfusion
Center, USL7 (Iglesias, Italy), were utilized as controls. Relevant characteristics of the three groups
are summarized in Table 1. All β-TM patients received regular long-term transfusion and iron-
chelating therapy. The criteria for the β-TI selection were transfusion independence and lack of a
regular iron chelation because of poor adherence or side effects. The study was approved by the
local ethics committees and informed consent was given by patients and controls.
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5Blood samples were collected from each subject and transported on ice at the Department of
Biomedical Sciences and Technologies, University of Cagliari (Cagliari, Italy).
Hematologic analysis
Hemoglobin (Hb) was determined by automatic procedures. Serum iron and total iron-binding
capacity were measured by using a commercial kit (Sigma-Aldrich). Transferrin saturation was
calculated as percentage of serum iron/total iron-binding capacity. Serum ferritin levels were
obtained by using an enzyme-linked immunosorbent assay (BioRad); serum erythropoietin and
hepcidin were analyzed using commercially available ELISA kits (R&D Systems Inc. Minneapolis,
United States and DRG Instruments GmbH, Germany, respectively). TC and HDL-C were
determined in serum by routine colorimetric enzymatic procedures (Sclavo Diagnostics
International S.r.l. Sovicille, Italy).
Isolation of PBMCs
Blood samples were centrifuged at 2200 rpm for 15 min to separate plasma. Plasma was removed
and the buffy coat collected. PBMCs were isolated by density gradient centrifugation (Lymphoprep;
density, 1.077 g/L; Nycomed Pharma, Oslo, Norway) at 1200 rpm for 10 minutes at 20°C, and
washed  twice  with  Hanks  balanced  salt  solution  (HBSS) and immediately used for experiments.
The trypan blue exclusion test was used to assess cell viability..
Neutral lipid staining
To visualize the degree of cytoplasmic neutral lipid (NL) accumulation, PBMCs were washed three
times with PBS, and fixed by soaking in 10% formalin. Cells were then treated with isopropyl
alcohol  (60%),  washed,  and  stained  with  oil  red  O  (ORO)  (a  lipid-soluble  dye  which  stains  NL,
including CE, but not free cholesterol).  They appear as bright red spots in the cytoplasm, and are
then counterstained with Mayer’s hematoxylin. After staining, cells were imaged using a Leitz
inverted-phase microscope fitted with a digital camera. At least two different fields per sample were
imaged and analyzed. The red intensity was scored on a semi-quantitative scale (from 0 to 4) by two
blinded observers: 0 indicated no staining; 1, rare positive cells or staining barely visible at low
power (×200); 2, focal staining or faint diffuse staining clearly visible at low power; 3, multifocal
staining or moderate diffuse staining; and 4, intense diffuse staining. There was significantly high
correlation between the scores of the two observers (r2= 0.96; P= 0.000). For convenience, scores
from only one observer were used for cell mean-score calculation.
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6Reverse transcription polymerase chain reaction (RT-PCR) and southern blotting analysis
mRNA levels for genes of interest were evaluated by RT-PCR and Southern blotting. Total RNA
was extracted from approximately 106 cells using TRIZOL reagent (Invitrogen Corporation,
Carlsbad, CA). Equal amounts of total RNA (1 μg) were reverse transcribed into cDNA using the
random hexamer method and amplified by PCR in the presence of primers specific for each gene
examined, according to the manufacturer’s instructions (GeneAmp RNA PCR Kit, Perkin-Elmer
Cetus, Norwalk, CT). Preliminary experiments demonstrated that these PCR conditions were within
the linear range of amplification of gene fragments. Under our experimental conditions, PCR
products separated on agarose and stained with ethidium bromide, showed a major band of the
predicted gene size (data not shown). During PCR reaction the non-radioactive label Digoxigenin-
11-dUTP (DIG) (Roche Applied Science, Mannheim, Germany) was incorporated and the DNA
fragments separated by electrophoresis in agarose were blotted onto a nylon membrane for 16 h in
10×SSC. The blot was exposed to X-ray film (Kodak X-OMAT) for 2–10 min in an X-ray cassette
at room temperature. The overall procedure was standardized by expressing the amount of PCR
products for the mRNA relative to the amount of product formed for β-actin. The National Institutes
of Health Image 1.63 Analysis Software program (Scion Image) was used to assess the intensity of
the bands in the autoradiograms.
Statistical analysis
Data were reported as mean ± standard deviation (SD). Statistical analyses were performed with the
software Origin (Microcal, Inc, Northampton, MA), and Statistica (StatSoft, Tulsa, OK). Statistical
comparisons between the three groups were made by using a one-way ANOVA and where
appropriate a post hoc Bonferroni test. A probability of P < 0.05 was considered statistically
significant.
Results
Iron metabolism parameters of patients and controls
Characteristics  of  enrolled  subjects  are  shown  in  Table  1.  Sixty-four  patients  in  the  β-TM  group
were anti-HCV positive, while only three in the β-TI one. Erythropoietin levels were higher, and Hb
levels lower, in β-TI compared to β-TM and controls.
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7Table 1. Characteristics of enrolled subjects. Values are expressed as mean ± SD.
*P=0.016 β-TI vs β-TM.
** By using the one-way ANOVA test the three groups differ in a statistically significant manner (P= 0.000).
§ Significant differences (P < 0.05) by Bonferroni's multiple comparison test.
Subjects Male AGE Anti-HCV
positive
Erythropoietin
(mU/ml)**
Hb
(g/dl)**
Control
(n =92)
60 40.7±11.3 0 35.1±9.0 14.8±0.6
β-TM
 (n=70)
27 38.0±5.0* 64 73.8±57.8§ 10.9±0.7§
β-TI
 (n=22)
14 44.1±8.2* 3 409.8±150.0§ 8.5±0.5§
Serum iron status indicators are shown in Table 2. Despite the great variability, levels of serum iron
and transferrin saturation were significantly higher in β-TI compared to both controls and β-TM. By
contrast, transferrin and hepcidin levels were lower in β-TI patients. Serum ferritin levels, which are
in equilibrium with the total amount of iron stored in the body, were prominent in β-TM patients.
However, they were also significantly higher in β-TI compared to controls.
Table 2. Serum iron status indicators in enrolled subjects. Values are expressed as mean ± SD.
* By using the one-way ANOVA test the three groups differ in a statistically significant manner (P < 0.001).
** Significant differences (P < 0.05) by Bonferroni's multiple comparison test.
Subjects Serum iron*
(µg/dl)
Transferrin*
test (mg/dl)
Transferrin*
saturation
(%)
Ferritin*
(ng/ml)
Hepcidin*
(ng/ml)
Control
(n =92)
115. 9±12.0 300.1± 5.0 31.0± 9.0 170.0±20.1 159.7±21.7
β-TM
(n=70)
126.3±16.1** 270.2±10.6** 43.7±11.9** 1057.3±800.9** 161.2±33.0**
β-TI
 (n=22)
170.3±19.2** 163.2±6.8** 70.2±13.0** 504.5±427.1** 117.5±29.1**
Changes in iron status indicators in serum from β-TI patients were associated with altered
expressions  in  PBMCs  of  genes  involved  in  some  way  in  the  regulation  of  iron  homeostasis.  In
particular,  hepcidin  and  IL-1α mRNA  levels  were  lower  and  TNFα mRNA  was  higher  in  β-TI
compared to β-TM and controls.
N
at
ur
e 
Pr
ec
ed
in
gs
 : 
hd
l:1
01
01
/n
pr
e.
20
10
.4
16
9.
1 
: P
os
te
d 
21
 J
an
 2
01
0
8hepcidin
IL1α
TNFα
β-actin
Controls β-TM β-TIA
B
hepcidin IL-1 TNF
0,0
0,5
1,0
1,5
2,0
TNFaIL-1a
m
RN
A
 le
ve
ls
 (t
ar
ge
t g
en
e/
b-
ac
tin
 Controls
b-TM
b-TI
hepcidin
Figure 1. Hepcidin, IL-1α and TNFα mRNA levels in controls, β-TM and β-TI. Total mRNA was extracted from
106 unstimulated cells. mRNA levels were determined by RT-PCR using the appropriate primer sets. Specific
bands were detected after addition of a chemiluminescent substrate, and analyzed by the NIH Image 1.63
program (Scion Image). (A) Representative blots. (B) Densitometric analysis of mRNA levels, normalized for the
endogenous β-actin mRNA Data values are represented as mean ± SD. Statistical analysis performed by using
the one-way ANOVA test showed highly significant differences between the groups (P= 0.000). This was followed
by Bonferroni's multiple comparison test (P < 0.05 between the groups linked by square brackets).
Serum lipid profiles of enrolled subjects
In agreement with studies by other authors 12,13, TC and HDL-C significantly decreased in both β-
TM and β-TI. However, by calculating the HDL-C/TC, ratio percentage was significantly lower in
β-TI compared to β-TM and controls (Figure 2). These results indicate that, unlike that in β-TM, the
TC reduction in β-TI is largely attributable to decreased cholesterol levels in the HDL fraction.
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Figure 2. Plasma lipid profile of enrolled subjects. Data are expressed as mean ± SD. Statistical analysis
performed by using the one-way ANOVA test showed highly significant differences between the groups (P=
0.000). This was followed by Bonferroni's multiple comparison test (P < 0.05 between the groups linked by
square brackets).
It is well known that depressed HDL-C levels are significantly and independently associated with an
increased risk of coronary death.15,16 This is commonly attributed to the ability of HDL to remove
cellular cholesterol excess by interacting with ABCA-1, a transmembrane protein expressed on the
surface of cells, including mononuclear blood cells.
In order to verify this possibility we next determined lipid content in PBMCs by staining cells with
ORO, a lysochrome fat-soluble dye widely used to demonstrate the presence of NL (mainly CE and
triglycerides) which appear as bright red spots in the cytoplasm, as described above in Materials and
Methods. As shown in Figures 3A and 3B, NL in control PBMCs were generally absent or very low
(mean score 0.6±0.3). PBMCs from β-TM had ORO staining levels scoring 1-2 (mean 1.6±0.8)
while those from β-TI had ORO levels scoring 2-4 (mean 2.6±1.3). It is important to note that most
unstimulated PBMCs freshly isolated from β-TI have a tendency to form cellular clusters (Figure
3A), hence resembling cultured PBMCs after mitogen activation. This phenomenon was not
observed in PBMCs from controls and β-TM (Figure 3A). This finding may have biological
significance, to the extent that PBMCs from β-TI patients may be grow-activated in vivo.
N
at
ur
e 
Pr
ec
ed
in
gs
 : 
hd
l:1
01
01
/n
pr
e.
20
10
.4
16
9.
1 
: P
os
te
d 
21
 J
an
 2
01
0
10
Control
β-TM
β-TI
0
1
2
3
4
5
FemalesMales
O
RO
 g
ra
di
ng
 Controls
b-TM
b-TI
Total
A B
Figure 4. ORO staining in controls, β-TM and β-TI. For these experiments, PBMCs were , immediately after
separation, collected, washed and fixed by soaking in 10% formalin, stained with ORO for NL, and counter-
stained with Mayer’s hematoxylin for nuclei. Cells were then examined by light microscopy and two different
fields per sample were imaged. Red ORO intensity was measured in these two fields using NIH Image J software.
(A) representative ORO-staining images. (B) ORO grading ± SD. Statistical analysis performed by using the one-
way ANOVA test showed highly significant differences between the groups (P= 0.000). This was followed by
Bonferroni's multiple comparison test (P < 0.05 between the groups linked by square brackets).
The above results were further supported by mRNA-level analysis of genes involved in the
regulation of cholesterol homeostasis. As shown in Figures 5A and 5B, ACAT-1 mRNA levels
significantly increased in both β-TM and β-TI compared to controls. However, ACAT-1 in β-TI
was higher than in β-TM. By contrast, nCEH mRNA levels were markedly reduced in β-TI, but not
in β-TM. ABCA1 mRNA levels do not vary in β-TM, while slightly decreasing in β-TI.
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Figure 5 . ACAT-1, nCEH and ABCA1 mRNA levels in controls, β-TM and β-TI. Total mRNA was extracted
from 106 unstimulated cells. mRNA levels were determined by RT-PCR using the appropriate primer sets.
Specific bands were detected after addition of a chemiluminescent substrate, and analyzed by the NIH Image
1.63 program (Scion Image). (A) Representative blots. (B) Densitometric analysis of mRNA levels, normalized
for the endogenous β-actin mRNA Data values are represented as mean ± SD. Statistical analysis performed by
using the one-way ANOVA test showed highly significant differences between the groups (P= 0.000). This was
followed by Bonferroni's multiple comparison test (P < 0.05 between the groups linked by square brackets).
Discussion
Cardiovascular complications are frequently observed in β-thalassemic patients; nevertheless the
pathogenesis of these life-threatening consequences is not yet completely understood.
The data presented here show that long-term transfusions and iron-chelating therapy partially
normalizes in β-TM most of the parameters which have been reported to be involved in the
pathogenesis of cardiovascular abnormalities in β-thalassemias.1 In particular, we found that in β-
TM, levels of serum iron, transferrin, transferrin saturation, erythropoietin and hepcidin did not
greatly differ from control values. Hepcidin and ILα mRNA levels were also comparable to controls
in PBMCs from β-TM patients, while TNFα mRNAs were slightly lower. This last finding was not
surprising since it has been reported that iron chelators inhibit TNFα expression.17,18
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However, despite a regular program of transfusions and iron chelating therapy, serum ferritin levels
remained high in β-TM patients. Considering that 1 ng/ml of serum ferritin corresponds to about 8
mg of stored iron it can be calculated that β-TM patients have more than eight times organ-stored
iron (8.5g) compared to controls (1.3g).19 These results support the hypothesis that when cardiac
dysfunction occurs in β-TM, it is likely due to heart iron overload.
On the other hand, different clinical pictures may be involved in cardiovascular complications
occurring in β-TI. In these patients, in fact, serum iron, transferrin saturation and erythropoietin
levels were higher, while those of transferrin and hepcidin were lower compared to both β-TM and
controls. Hepcidin and ILα mRNA levels were found to be lower in β-TI-PBMCs, while those of
TNFα mRNA  were  higher.  These  results  indicate  that  in  β-TI,  low  ILα levels,  coupled  with
persistent bone marrow hyperplasia, secondary to ineffective erythropoiesis-dependent anemia,
bring about inappropriate chronic hepcidin suppression. Loss of functioning hepcidin raises serum
iron levels, decreases reticulo-endothelial iron stores, and increases intestinal iron absorption.9,10
Therefore the consequent free serum iron increase may induce lipid peroxidation, endothelial cell
activation, and reactive oxygen species generation, all of which are considered important early
events in the pathogenesis of atherosclerosis.20
Hypocholesterolemia has been frequently described in thalassemic subjects, and for this reason a
lower incidence of atherosclerotic events in these subjects has even been suggested.21,22 In spite of
this, the exact mechanism/s and the possible clinical consequences of hypocholesterolemia in
thalassemic patients have not yet been elucidated. It has been recently demonstrated that patients
with chronic anemia and increased erythropoietic activity have hypocholesterolemia, whereas those
with low erythropoietic activity are normo-cholesterolemic,23 suggesting that in the former
hypocholesterolemia is related to a higher cholesterol requirement by erythroid cells in order to
sustain cellular growth. In the present study we confirmed that patients with β-TI had significantly
lower total and HDL cholesterol, not only compared to controls but also compared with β-TM
patients. Additionally, we also showed that PBMCs isolated from β-TI patients accumulated more
neutral  lipids,  mainly  CE,  in  their  cytoplasm,  compared  to  PBMCs from β-TM and controls.  RT-
PCR analysis also revealed that ACAT-1 mRNA levels were significantly higher in β-TI, compared
to β-TM, while nCEH mRNA levels were slightly reduced. These data clearly indicate that, in β-TI,
bone marrow progenitor cells entrapped more neutral lipids to sustain active growth. As a
consequence, total and HDL cholesterol may decrease.
Although further studies are needed in order to fully understand the pathogenesis of cardiovascular
disorders in thalassemic patients, the results of the present study offer us a way to speculate on the
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possible mechanism/s by which thalassemic patients not only are not protected against
atherosclerosis, but may even be considered at a higher risk of developing this severe condition.
It  is  well  known  that  transendothelial  migration of monocytes and lymphocytes is a fundamental
mechanism in atherogenesis,20 this process being partly mediated by the interaction of carbohydrate
ligands present on leukocyte membranes with adhesion molecules24 present  on  the  surface  of  the
activated endothelium cells.
NMR spectroscopy studies have shown that the majority of non-transferrin-bound iron (NTBI) in
the plasma of iron-overloaded patients is present as Fe3+ complexes with citrate.25 Using this iron
complex as the source of free iron in the incubation medium, Kartikasari et al.,26 showed that
10µmol/L of iron directly activates and stimulates the expression of adhesion molecules on both
umbilical-vein endothelial cells and monocytes, as well as promoting monocyte adhesion to
endothelial cells. It has also been demonstrated that up-regulation of TNFα enhances adhesion
molecule expression in epithelial cells 27
β-TI patients enrolled for this study exhibited high plasma transferrin saturation as well as high
TNFα mRNA levels in their PBMCs, indicative of chronic endothelial activation. In addition,
accumulation of CE, the main components of atherosclerotic plaque fatty lesions, was also found in
mononuclear cells from these patients. Hence it may be supposed that, in β-TI patients, high free
serum iron levels, besides causing a direct toxic effect through oxygen radical production, may also
play an independent role in promoting leukocyte recruitment to the endothelium. As a result, CE-
rich leukocytes migrate into vessel walls, thus accelerating the atherosclerotic process. These
conclusions fit well with the finding that β-TI-PBMCs tend to form clusters in vitro, which is
indicative of growth activation in vivo. If this hypothesis is correct, it may be argued that any
chronic anemia associated with high-erythropoietic activity including silent carrier state (β-TMI),
which in Sardinia affects about 12% of the population, may increase the risk of developing
atherosclerosis. Accordingly, Sarnak et al.28 found in a study cohort (14,410 subjects total)
significant increase of cardiovascular disease in chronic anemic subjects.
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